Wikipedia -WSS

Wikipedia

author：focus 2025-09-28 21:58:31 - browse：57

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Google and Epic fight stronger regulation of AI in health care

explore

WSS

Life sciences investors close nearly $6 billion in new funds

Medicare has a new plan to address drug shortages

Readout LOUD podcast: ESMO highlights & Roivant's big deal

As digital health tech proliferates, a new institute aims to cut through hype

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Gene therapy’s promise and the high cost of hope

hotspot

Wikipedia

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

How Medicaid coverage policies for immigrants impact new moms

Alkermes shareholders re

Google and Epic fight stronger regulation of AI in health care

DIEP, the 'gold standard' of breast reconstruction, is under threat

What is microchimerism and how does it affect maternal health?

BioMarin wins approval for gene therapy to treat hemophilia A

Prime Medicine says its gene editing passes test in monkeys

How to save PrEP access — and even expand it

Why hospitals are withdrawing from US News rankings

focus

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Why hospitals are withdrawing from US News rankings

Medicare must police algorithms in Medicare Advantage, Dems say

Medicare proceeds with plan to claw back hospital funds

Bill would allow buprenorphine prescription for addiction via telehealth

Brain injuries and the importance of a second opinion

focus

leisure time

explore

focus